Online inquiry

IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12863MR)

This product GTTS-WQ12863MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TLR2 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001318787.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7097
UniProt ID O60603
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12863MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3939MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ13028MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ13706MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ7653MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ12916MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ14305MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ5750MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ11948MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLTA3698A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW